(19)
(11) EP 4 798 583 A1

(12)

(43) Date of publication:
02.09.2026 Bulletin 2026/36

(21) Application number: 24805934.7

(22) Date of filing: 25.10.2024
(51) International Patent Classification (IPC): 
C07D 405/14(2006.01)
A61K 31/352(2006.01)
 A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 405/14; A61P 35/00; A61K 31/444
(86) International application number:
PCT/US2024/053017
(87) International publication number:
WO 2025/090905 (01.05.2025 Gazette 2025/18)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 26.10.2023 WO PCT/CN2023/126940

(71) Applicant: Nested Therapeutics, Inc.
Cambridge, MA 02138 (US)

(72) Inventors:
  • STEINHUEBEL, Dietrich
    Cambridge, MA 02138 (US)
  • ZHU, Yuling
    Shanghai, 200131 (CN)
  • WANG, Xiaoyang
    Shanghai, 200131 (CN)

(74) Representative: Potter Clarkson 
Chapel Quarter Mount Street
Nottingham NG1 6HQ
Nottingham NG1 6HQ (GB)

   


(54) CRYSTALLINE FORMS OF 3-[[3-FLUORO-2-(METHYLSULFAMOYLAMINO)-4-PYRIDYL]METHYL]-7-[(3-FLUORO-2-PYRIDYL)OXY]-4-METHYL-CHROMEN-2-ONE